Johns Hopkins is supporting research to learn more about COVID-19 and the SARS-CoV-2 virus. One of the studies is investigating whether an oral drug called hydroxychloroquine (brand name Plaquenil) is better than placebo in preventing COVID-19 infection in healthy people working in health care settings.
Known as the Healthcare Worker Exposure Response & Outcomes of Hydroxychloroquine HERO-HCQ Trial, the study is supported by the Patient-Centered Outcomes Research Institute and is being conducted at over 30 sites, including Johns Hopkins, where the study is led by Dr. Mark Sulkowski, professor of medicine (IRB00249289).
All people working in health care who provide care, supplies, or services to patients—such as nurses, therapists, physicians, emergency responders, food service workers, environmental services workers, interpreters, and transporters—are invited to join. The study is open at Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center, Howard County General Hospital, Suburban Hospital, Sibley Memorial Hospital, and Green Spring Station.
Contact the study team directly by email at kward27@jhmi.edu or call/text at 410-314-1137. To participate in this or any other study available to JHM hospital workers, visit https://ictr.johnshopkins.edu/coronavirus/hcw-studies. Your participation in any of these studies is voluntary, and your job will not be jeopardized if you decide not to participate.
